Company profile: Arrakis Therapeutics
1.1 - Company Overview
Company description
- Provider of RNA-targeted drug discovery tools and small-molecule therapeutics, including the rSM Toolkit to identify RNA substructures, Direct Modulators that bind RNA, Targeted RNA Degraders, and Covalent Modifiers that block translation. Maintains pipeline programs for cancer, cardiovascular conditions, neurodegeneration, and rare diseases, including an rSM program for DM1.
Products and services
- Targeted RNA Degraders: Conjugate-based rSM-ligand assemblies engineered to degrade specific RNA targets via rSM-ligand conjugation, applied to structure-defined RNAs for target-specific degradation
- RSM Toolkit: Structure-guided platform developed to identify RNA substructures and prosecute RNA targets, integrating conventional small-molecule discovery tools with new RNA structure-based drug design methodologies
- Direct Modulators: Small-molecule products that directly bind defined RNA structures to modulate function, impacting disease biology through precise, target-specific engagement of RNA conformational features
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arrakis Therapeutics
AvidBiotics
HQ: United States
Website
- Description: Provider of biotherapeutics deploying a biotechnology-derived technology platform with multiple applications in life sciences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AvidBiotics company profile →
Automated Lab Solutions
HQ: Germany
Website
- Description: Provider of life science robotics and automation, including the CellCelector automated system for fluorescence imaging, selection, and image-based sorting/picking of single cells, clusters, adherent cell colonies, and clones from semi-solid media; rare single cell isolation; single cell cloning; stem cell picking; the Incubator FlowBox laminar flow cabinet; and automation components.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Automated Lab Solutions company profile →
Nutcracker Therapeutics
HQ: United States
Website
- Description: Provider of mRNA therapeutics and an integrated RNA manufacturing platform: the Nutcracker Manufacturing Unit (NMU) for rapid mRNA production from DNA sequences; GMP-in-a-box to lower costs and cycle times; CodonCracker software to optimize RNA sequences; Nutshell delivery vehicles; an RNA therapeutics pipeline across HPV-driven tumors, T cell lymphoma, and genitourinary tumors; and strategic collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nutcracker Therapeutics company profile →
OXGENE
HQ: United Kingdom
Website
- Description: Provider of versatile cloning plasmids for research, custom cloning and DNA synthesis, and IP-free products. Offers TESSA technology for scalable, cost-effective AAV manufacturing, high-titre transient rAAV production, cell and gene therapy acceleration services (including CAR-T), cell line development and engineering, and LentiVEX plasmids and cell lines for lentiviral vector production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OXGENE company profile →
Brahms
HQ: Germany
Website
- Description: Provider of biomarker-based diagnostic test procedures and automated immunoanalyzers (KRYPTOR) using TRACE technology to improve diagnosis and treatment of life-threatening illnesses. Offerings include biomarkers for prenatal screening, oncology and thyroid disease management; sFlt-1/PlGF for preeclampsia risk; CgA II for neuroendocrine tumor monitoring; TRAK human for Graves’ disease; and Copeptin proAVP for water balance and acute myocardial infarction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brahms company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arrakis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arrakis Therapeutics
2.2 - Growth funds investing in similar companies to Arrakis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arrakis Therapeutics
4.2 - Public trading comparable groups for Arrakis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →